BioCentury | Sep 4, 2019
Financial News

Vir plots IPO as more programs near clinic

...has built its technology platforms via acquisitions and deals. It has acquired Humabs BioMed S.A., TomegaVax Inc....
BioCentury | Jun 2, 2018
Strategy

Partnering on a mission

...and other indications, and gained a cytomegalovirus (CMV) vector-based vaccine technology through the acquisition of TomegaVax Inc....
BioCentury | May 11, 2018
Company News

Vir acquires antiviral gene-editing biotech Agenovir

...software and RNAi technology, adding to cytomegalovirus (CMV) vector-based vaccine technology gained through acquisition of TomegaVax Inc....
...Francisco, Calif. Agenovir Corp., South San Francisco, Calif. Business: Infectious Jennie Walters Agenovir Corp. Alnylam Pharmaceuticals Inc. Humabs BioMed S.A. TomegaVax Inc. Vir...
BioCentury | May 9, 2018
Company News

Vir acquires antiviral gene-editing biotech Agenovir

...RNAi technology, adding to cytomegalovirus (CMV) vector-based vaccine technology gained through its 2017 acquisition of TomegaVax Inc....
BioCentury | Oct 19, 2017
Emerging Company Profile

Anti-bug big house

...adding to the cytomegalovirus (CMV) vector-based vaccine technology it obtained through its January acquisition of TomegaVax Inc....
BioCentury | Jan 7, 2017
Financial News

Scangos to lead anti-infectives newco Vir

...treat infectious diseases. Vir said it will use viral vectors obtained via its acquisition of TomegaVax Inc....
BioCentury | Oct 10, 2013
Distillery Therapeutics

Indication: Infectious disease

...viral DNA or RNA levels that were indistinguishable from vaccinated, unchallenged macaques. Planned work by TomegaVax Inc....
...doi:10.1038/scibx.2013.1099 Published online Oct. 10, 2013 Patented by Oregon Health & Science University; licensed to TomegaVax...
Items per page:
1 - 7 of 7
BioCentury | Sep 4, 2019
Financial News

Vir plots IPO as more programs near clinic

...has built its technology platforms via acquisitions and deals. It has acquired Humabs BioMed S.A., TomegaVax Inc....
BioCentury | Jun 2, 2018
Strategy

Partnering on a mission

...and other indications, and gained a cytomegalovirus (CMV) vector-based vaccine technology through the acquisition of TomegaVax Inc....
BioCentury | May 11, 2018
Company News

Vir acquires antiviral gene-editing biotech Agenovir

...software and RNAi technology, adding to cytomegalovirus (CMV) vector-based vaccine technology gained through acquisition of TomegaVax Inc....
...Francisco, Calif. Agenovir Corp., South San Francisco, Calif. Business: Infectious Jennie Walters Agenovir Corp. Alnylam Pharmaceuticals Inc. Humabs BioMed S.A. TomegaVax Inc. Vir...
BioCentury | May 9, 2018
Company News

Vir acquires antiviral gene-editing biotech Agenovir

...RNAi technology, adding to cytomegalovirus (CMV) vector-based vaccine technology gained through its 2017 acquisition of TomegaVax Inc....
BioCentury | Oct 19, 2017
Emerging Company Profile

Anti-bug big house

...adding to the cytomegalovirus (CMV) vector-based vaccine technology it obtained through its January acquisition of TomegaVax Inc....
BioCentury | Jan 7, 2017
Financial News

Scangos to lead anti-infectives newco Vir

...treat infectious diseases. Vir said it will use viral vectors obtained via its acquisition of TomegaVax Inc....
BioCentury | Oct 10, 2013
Distillery Therapeutics

Indication: Infectious disease

...viral DNA or RNA levels that were indistinguishable from vaccinated, unchallenged macaques. Planned work by TomegaVax Inc....
...doi:10.1038/scibx.2013.1099 Published online Oct. 10, 2013 Patented by Oregon Health & Science University; licensed to TomegaVax...
Items per page:
1 - 7 of 7